Explore 3 Stock Ideas & Industry Insights Download Free Report

Morphic Holding Inc

Company price
None USD 0.00(0%)
Last update at 2024-09-26T03:06:11.318019Z
Market Cap
1541.63M

Momentum Score

…

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
19.34
Low
63.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-31.25M
Debt / Equity
0.00
ROE
-29.58%
Net Debt
-56.23M
ROCE
-9.23%
Diluted EPS TTM
-3.59

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -58.97M -95.54M -45.57M -42.42M -23.83M
Net income -59.04M -94.24M -45.00M -43.33M -23.83M
Selling general administrative 32.14M 27.81M 18.50M 10.23M 5.36M
Gross profit 70.81M 19.79M 44.95M 16.98M 3.36M
Reconciled depreciation 1.00M 1.03M 1.13M 0.82M 0.54M
Ebit -64.40M -96.84M -48.31M -46.99M -24.63M
Ebitda -63.40M -95.81M -47.18M -46.17M -24.09M
Depreciation and amortization 1.00M 1.03M 1.13M 0.82M 0.54M
Non operating income net other - - 1.61M - -
Operating income -63.40M -95.81M -47.18M -46.99M -24.63M
Other operating expenses 134.20M 115.60M 92.12M 63.97M 27.99M
Interest expense 4.57M 0.27M 2.74M 4.57M 0.00M
Tax provision 0.07M 0.00M -0.57M 0.91M 0.00M
Interest income 4.57M 0.27M 1.63M 4.67M 0.87M
Net interest income 4.57M 0.27M 1.63M 4.67M 0.87M
Income tax expense 0.07M -1.30M -0.57M 0.91M 0.80M
Total revenue 70.81M 19.79M 44.95M 16.98M 3.36M
Total operating expenses 134.20M 115.60M 92.12M 63.97M 27.99M
Cost of revenue - - - 53.73M 22.63M
Total other income expense net 4.42M 0.26M 1.61M 4.57M -0.07M
Net income from continuing ops -59.04M -95.54M -45.00M -43.33M -23.83M
Net income applicable to common shares -59.04M -95.54M -45.00M -43.33M -23.83M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 722.51M 368.59M 426.29M 242.38M 247.44M
Other current assets 12.58M 13.93M 10.20M 11.17M 3.09M
Total liab 25.49M 19.47M 89.59M 97.19M 106.52M
Total stockholder equity 697.02M 349.12M 336.70M 145.20M 140.92M
Deferred long term liab - - - 57.75M -
Other current liab 17.08M 11.69M 11.63M 39.44M 6.73M
Common stock 0.01M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.00M 0.00M 0.00M 0.00M
Retained earnings -449.19M -297.10M -238.05M -142.51M -97.51M
Other liab - - 51.33M 57.75M 71.17M
Other assets - 0.77M 7.96M 0.34M 0.42M
Cash 58.58M 59.27M 408.13M 228.26M 101.56M
Total current liabilities 24.78M 17.13M 38.26M 39.44M 35.35M
Current deferred revenue -1.63M 0.47M 20.63M 25.27M 23.45M
Net debt -56.23M -55.43M -403.09M -228.26M -101.56M
Short term debt 1.63M 1.49M 1.21M -29.11M -
Short long term debt total 2.34M 3.84M 5.05M - -
Other stockholder equity 1143.92M 649.55M 575.23M 287.73M -9.05M
Property plant equipment - 5.63M 7.39M 2.61M 3.45M
Total current assets 716.93M 362.18M 418.33M 239.44M 243.57M
Net tangible assets - 349.12M 336.70M 145.20M 140.92M
Short term investments 645.77M 288.98M 236.70M 126.22M 135.46M
Net receivables 0.00M 0.46M 2.31M 7.31M 3.47M
Inventory - -0.46M -2.31M -7.31M -
Accounts payable 7.70M 3.48M 4.80M 3.85M 5.17M
Accumulated other comprehensive income 2.29M -3.34M -0.48M -0.02M 0.04M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -142.51M -
Non currrent assets other 0.13M 0.77M 0.57M 0.34M 0.42M
Non current assets total 5.59M 6.41M 7.96M 2.95M 3.86M
Capital lease obligations 2.34M 3.84M 5.05M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -56.45M -112.16M 8.72M -135.99M -0.66M
Change to liabilities -69.20M -13.85M -9.02M 0.93M 97.50M
Total cashflows from investing activities -56.45M -113.18M 8.18M -135.99M -0.66M
Net borrowings - - - - -0.65M
Total cash from financing activities 45.27M 266.31M 38.30M 93.30M 89.47M
Change to operating activities -5.59M -2.51M 2.76M 1.35M 1.05M
Net income -59.04M -95.54M -45.00M -43.33M -23.83M
Change in cash -112.16M 69.67M 0.49M -84.34M 165.15M
Begin period cash flow 171.99M 102.32M 101.83M 186.18M 21.02M
End period cash flow 59.83M 171.99M 102.32M 101.83M 186.18M
Total cash from operating activities -100.98M -83.46M -45.99M -41.65M 76.34M
Issuance of capital stock 39.21M 265.22M 33.65M 93.27M 90.12M
Depreciation 1.00M 1.03M 1.13M 0.82M 0.54M
Other cashflows from investing activities - - - -133.83M 0.00M
Change to inventory - -2.51M 2.83M 1.41M -
Change to account receivables 1.85M 5.01M -3.85M -3.47M -3.47M
Sale purchase of stock 0.89M 1.09M 1.11M 93.30M 90.12M
Other cashflows from financing activities 5.17M -113.18M 3.53M 0.03M 90.12M
Change to netincome 30.00M 22.40M 11.05M 2.04M 1.07M
Capital expenditures 0.36M 1.02M 0.54M 2.16M 0.66M
Change receivables - - -3.85M - -
Cash flows other operating - - -0.76M - -
Cash and cash equivalents changes - - 0.49M - -
Change in working capital -72.94M -11.35M -13.62M -1.19M 98.56M
Stock based compensation 29.05M 21.18M 11.05M 3.53M 1.00M
Other non cash items 0.95M 1.22M 0.45M -0.02M 0.04M
Free cash flow -101.34M -84.48M -46.53M -43.81M 75.68M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

35 Gatehouse Drive, A2, Waltham, MA, United States, 02451

781 996 0955

124

Name Title Year Born
Dr. Praveen P. Tipirneni M.D. CEO, MD & Director 1968
Dr. Bruce N. Rogers Ph.D. Pres 1969
Dr. Timothy A. Springer Ph.D. Founder, Independent Director & Member of Scientific Advisory Board 1948
Dr. Marc Schegerin M.B.A., M.D. CFO & COO 1976
Mr. William D. DeVaul Esq. Gen. Counsel & Sec. 1971
Mr. Robert E. Farrell Jr., CPA, CPA Sr. VP of Fin. & Operations and Chief Accounting Officer 1965
Dr. Blaise Lippa Ph.D. Chief Scientific Officer NA
Mr. Aaron Pelta Sr. VP of Bus. & Corp. Devel. NA
Ms. Joanne Gibbons Sr. VP of Regulatory Affairs NA
Dr. Bruce N. Rogers Ph.D. President & Interim Principal Executive Officer 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…